These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2485 related articles for article (PubMed ID: 7820457)
1. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Killion JJ; Fidler IJ Immunomethods; 1994 Jun; 4(3):273-9. PubMed ID: 7820457 [TBL] [Abstract][Full Text] [Related]
2. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Killion JJ; Fidler IJ Pharmacol Ther; 1998 Jun; 78(3):141-54. PubMed ID: 9690815 [TBL] [Abstract][Full Text] [Related]
3. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418 [TBL] [Abstract][Full Text] [Related]
4. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Kurzman ID; Shi F; Vail DM; MacEwen EG Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295 [TBL] [Abstract][Full Text] [Related]
6. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice. Yoo YC; Saiki I; Sato K; Azuma I Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100 [TBL] [Abstract][Full Text] [Related]
7. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Fidler IJ; Fan D; Ichinose Y Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047 [TBL] [Abstract][Full Text] [Related]
8. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. Fidler IJ; Fogler WE; Brownbill AF; Schumann G J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979 [TBL] [Abstract][Full Text] [Related]
9. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801 [TBL] [Abstract][Full Text] [Related]
10. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases. Schroit AJ; Fidler IJ Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445 [No Abstract] [Full Text] [Related]
11. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Kleinerman ES; Maeda M; Jaffe N Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Utsugi T; Nii A; Fan D; Pak CC; Denkins Y; van Hoogevest P; Fidler IJ Cancer Immunol Immunother; 1991; 33(5):285-92. PubMed ID: 1868486 [TBL] [Abstract][Full Text] [Related]
13. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides. Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109 [TBL] [Abstract][Full Text] [Related]
14. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Dinney CP; Bucana CD; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ Cancer Res; 1991 Jul; 51(14):3741-7. PubMed ID: 1905975 [TBL] [Abstract][Full Text] [Related]
15. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542 [TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. Asano T; Kleinerman ES J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710 [TBL] [Abstract][Full Text] [Related]
17. Liposomes in the treatment of malignancy: a clinical perspective. Sugarman SM; Perez-Soler R Crit Rev Oncol Hematol; 1992; 12(3):231-42. PubMed ID: 1497823 [TBL] [Abstract][Full Text] [Related]
18. [Antimetastatic effect of a liposome-enclosed analog of muramyl dipeptide]. Umanskiĭ VIu; Stefanov AV; Bondar' OP; Balitskiĭ KP; Pinchuk VG Vopr Onkol; 1988; 34(4):433-8. PubMed ID: 2837005 [TBL] [Abstract][Full Text] [Related]
19. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes. Melissen PM; van Vianen W; Bidjai O; van Marion M; Bakker-Woudenberg IA Biotherapy; 1993; 6(2):113-24. PubMed ID: 8398570 [TBL] [Abstract][Full Text] [Related]
20. Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers. Drath DB Immunopharmacology; 1986 Oct; 12(2):117-26. PubMed ID: 3021650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]